753483-59-9Relevant academic research and scientific papers
PYRROLO[2,3-B]PYRIDINE CDK9 KINASE INHIBITORS
-
Page/Page column 383, (2014/09/29)
Disclosed are compounds of Formula (IIa), wherein R1, R2, R3A, R3B, R3C, R3D, R3E, and R4 are as defined in the specification, and pharmaceutically acceptable salts thereof. The compounds may be used as agents in the treatment of diseases, including cancer. Also provided are pharmaceutical compositions comprising one or more compounds of Formula (IIa)
Diaminopyrimidine and diaminopyridine 5-HT7 ligands
Denhart, Derek J.,Purandare, Ashok V.,Catt, John D.,Dalton King,Gao, Aiming,Deskus, Jeffrey A.,Poss, Michael A.,Stark, Arlene D.,Torrente, John R.,Johnson, Graham,Mattson, Ronald J.
, p. 4249 - 4252 (2007/10/03)
The present studies have identified a series of diaminopyrimidines and diaminopyridines as novel 5-HT7 receptor ligands. Three regiosiomeric classes of pyrimidines and four regioisomeric classes of pyridines were synthesized and analyzed for binding to the 5-HT7 receptor. The 5-HT7 binding affinities of different regioisomers show clearly the structure-activity relationship with position of ring nitrogens.
